eFT 508

Drug Profile

eFT 508

Alternative Names: eFT-508

Latest Information Update: 08 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Effector Therapeutics
  • Class Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma; Solid tumours
  • Preclinical Diffuse large B cell lymphoma

Most Recent Events

  • 20 Jun 2017 eFFECTOR Therapeutics, Pfizer and Merck agree to co-develop eFT 508 in combination with avelumab for Colorectal cancer
  • 20 Jun 2017 eFFECTOR Therapeutics plans a phase II trial for microsatellite stable relapsed or refractory Colorectal cancer in the third quarter of 2017
  • 05 Jun 2017 Safety, pharmacokinetics and pharmacodynamics data from a phase I part of phase I/II trial in Solid tumours released by eFFECTOR Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top